Mineralys Therapeutics (MLYS) Cash from Operations (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Cash from Operations of 39471000.0 for Q1 2026, down 4.1% sequentially from 37916000.0 in Q4 2025, and up 13.23% YoY from 34860442.63 in Q1 2025.
Mineralys Therapeutics (MLYS) Cash from Operations (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 39471000.0 in Q1 2026.
- Quarterly Cash from Operations rose 13.23% year-over-year to 39471000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 136400000.0 (up 29.2% YoY) and the FY2025 annual result came in at 142416000.0, up 14.37% from the prior year.
- Cash from Operations fell to 39471000.0 in Q1 2026 per MLYS's latest filing, from 37916000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 5469000.0 in Q2 2022 and troughed at 66843000.0 in Q4 2024.
- A 5-year average of 26976176.47 and a median of 28800000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations sank 272.76% in 2023, then soared 43.28% in 2025.
- Over 5 years, Cash from Operations stood at 10186000.0 in 2022, then slumped by 184.52% to 28981000.0 in 2023, then slumped by 130.64% to 66843000.0 in 2024, then jumped by 43.28% to 37916000.0 in 2025, then dropped by 4.1% to 39471000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 39471000.0, 37916000.0, and 28800000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | -32.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.53 Mn |
| Jun 30, 2026 | -32.53 Mn |
| Mar 31, 2026 | -39.47 Mn |
| Mar 31, 2026 | -39.47 Mn |
| Dec 31, 2025 | -37.92 Mn |
| Dec 31, 2025 | -37.92 Mn |
| Sep 30, 2025 | -28.80 Mn |
| Sep 30, 2025 | -28.80 Mn |
| Jun 30, 2025 | -30.21 Mn |
| Jun 30, 2025 | -30.21 Mn |
| Mar 31, 2025 | -45.49 Mn |
| Mar 31, 2025 | -45.49 Mn |
| Dec 31, 2024 | -66.84 Mn |
| Dec 31, 2024 | -66.84 Mn |
| Sep 30, 2024 | -50.19 Mn |
| Sep 30, 2024 | -50.19 Mn |
| Jun 30, 2024 | -30.15 Mn |
| Jun 30, 2024 | -30.15 Mn |
| Mar 31, 2024 | -19.14 Mn |
| Mar 31, 2024 | -19.14 Mn |